Bluebird bio

Yahoo Finance • 11 months ago

12 Most Promising Gene Editing Stocks According to Hedge Funds

In this piece, we will take a look at the 12 most promising gene editing stocks according to hedge funds. If you want to skip our take on how the gene editing industry sits right at the top of the global innovation food chain, then you can... Full story

Mentioned:

Yahoo Finance • 11 months ago

Down 30% in a Week, What in the World Is Going On With Bluebird Bio Stock?

A young scientist recording her findings on a tablet Despite the Food and Drug Administration (FDA) approving its sickle cell disease (SCD) gene therapy last week, Bluebird Bio (NASDAQ: BLUE) is having a very bad time right now. On Dec. 8... Full story

Mentioned:

CRSP
VRTX

Yahoo Finance • 12 months ago

bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

Outcomes-based contract offerings available to both commercial payers and Medicaid LYFGENIA will be available through bluebird’s established national network of Qualified Treatment Centers beginning in Q1 2024 "my bluebird support" patie... Full story

Yahoo Finance • last year

Bluebird Bio Inc (BLUE) Reports Q3 2023 Financial Results: Strong Commercial Launch and ...

Bluebird Bio Inc (NASDAQ:BLUE) reported a strong commercial launch for ZYNTEGLO and SKYSONA with 22 patient starts across both programs. The company ended the quarter with $227 million in cash, cash equivalents, marketable securities, and... Full story

Yahoo Finance • last year

Is Bluebird Bio Stock a Buy?

Once a rising star in the biotech industry, Bluebird Bio (NASDAQ: BLUE) has had a difficult past few years. Furthermore, Bluebird's market capitalization is just $314 million as of this writing, lower than many of its clinical-stage compet... Full story

Yahoo Finance • last year

11 Best High Short Interest Stocks To Buy Now

In this piece, we will take a look at the 11 best high short interest stocks to buy now. If you want to skip our introduction to short selling and short interest, then take a look at 5 Best High Short Interest Stocks To Buy Now. Short sel... Full story

Mentioned:

ALLO
BMEA
CVNA
SWTX
W

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of bluebird bio, Inc. – BLUE

NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE). Such investors are advised to contact Robert S. Willoughby at n... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE

NEW YORK, April 16, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE). Such investors are advised to contact Robert S. Willoughby at n... Full story

The FDA approved a first-of-its-kind treatment from Bluebird Bio that represents a potential cure for a rare blood disorder at a price of $2.8 million per patient.... Full story

Yahoo Finance • 2 years ago

Why Shares of Bluebird Bio, CRISPR Therapeutics, and Editas Medicine Soared This Week

Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by 17% over the holiday-shortened week as... Full story

Mentioned:

CRSP
EDIT

Yahoo Finance • 2 years ago

bluebird bio (Finally) Nears Approval. What's Next?

The gene therapy pioneer may earn approval years after initially teasing investors. It may not be time to celebrate.... Full story

Yahoo Finance • 2 years ago

FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions

Current standard of care relies on regular red blood cell transfusions and iron management that carry the risk of progressive multi-organ damage and increased risk of morbidity and mortality If approved, beti-cel will be the first potenti... Full story

Yahoo Finance • 2 years ago

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

If approved, eli-cel will be the first and only gene therapy for the treatment of early active CALD, a rare neurodegenerative disease that primarily affects young children and leads to irreversible loss of neurologic function and death PD... Full story